Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares |
Dec. 31, 2023 |
Dec. 31, 2022 |
---|---|---|
Private Placement - December 2020 | ||
Anti-dilutive securities | ||
Warrants issued to purchase common stock | 282,809 | 282,809 |
Private Placement September2022 | ||
Anti-dilutive securities | ||
Warrants issued to purchase common stock | 13,813,912 | 13,813,912 |
Tyme Merger | ||
Anti-dilutive securities | ||
Warrants issued to purchase common stock | 41,085 | 41,085 |
First Draw of Loan Agreement | ||
Anti-dilutive securities | ||
Warrants issued to purchase common stock | 2,754 | 2,754 |
Second Draw on Loan Agreement | ||
Anti-dilutive securities | ||
Warrants issued to purchase common stock | 1,738 | 1,738 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|